Tumors

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Ratein Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of OralAzacitidine Exelixis Reports Integrated Data From Phase II Clinical Trialsof XL999 at ASCO Clinical Data Reported on Vidaza in Hematologic Malignancies andAdva...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc.(NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN241, the Company's novel investigational mda-7/IL-24 tumorsuppressor agent, in patients with advanced solid tumors. The data (Abstract #380), which were presented today at theannual meeting of the American Society of Gene Therapy, showed thatin this 22-patie...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc.(Nasdaq: IMGN), a biopharmaceutical company that develops targetedanticancer therapeutics using its Tumor-Activated Prodrug (TAP)technology, today announced that clinical findings for threedifferent TAP compounds for the treatment of solid tumors are to bereported at the 43rd American Society of Clinical Oncology (ASCO)Annual...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by CombiningCytokines With Peregrine's Anti-PS Antibodies Demonstrate IncreasedAnti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of canc...

Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice

PHILADELPHIA, March 15, 2007-- The cause of one notoriouschildhood disease, poliovirus, could be used to treat the ongoingthreat of another childhood disease, neuroblastoma. In the March 15issue of Cancer Research, researchers from Stony Brook Universityreport that an attenuated -- or non-virulent -- form of poliovirusis effective in obliterating neuroblastoma tumors in mice, evenwhen th...